CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the closing of its public offering of 15,333,334 shares of its common stock at a price of $9.00 per share before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 2,000,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount.
